Drug Profile
Research programme: antibody-drug conjugates - Ambrx/Bristol-Myers Squibb
Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Ambrx; Bristol-Myers Squibb
- Developer Ambrx
- Class Antibodies; Drug conjugates; Immunotoxins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Mar 2024 Ambrx has been acquired by Johnson & Johnson
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 03 May 2013 Early research in Cancer in USA (Parenteral)